Piramal Enterprises Limited Inactive USPTO patentsUtility application

Utility

Pharmaceutical Combination for the Treatment of Cancer

2 Jun 22

The present invention relates to a pharmaceutical combination comprising a CDK inhibitor and at least one antioxidant enzyme inhibitor for use in the treatment of cancer.

Owe Orwar, Sreesha Srinivasa, Prabha Mishra

Filed: 13 Dec 21

Utility

Compounds for the Treatment of Cancers Associated with Human Papillomavirus

27 Jan 22

The present invention relates to the pyrrolidine substituted with flavone derivatives, represented by the compounds of Formula (I) or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a diastereoisomer thereof for use in the treatment of cancers associated with human papillomavirus.

Swati Ajay PIRAMAL, Muralidhara Padigaru, Veena R. Agarwal, Gandhali Ashwin Deshpande

Filed: 29 Sep 21

Utility

dtv5gjs4osw4zn h3hg97r

23 Dec 21

The present invention relates to a pharmaceutical combination comprising a cyclin dependent kinase (CDK) inhibitor represented by a compound of formula I (as described herein) or a pharmaceutically acceptable salt thereof; and at least one anticancer agent selected from a BRAF inhibitor or a MEK inhibitor, for use in the treatment of melanoma.

Veena AGARWAL, Giridharan PERIYASAMY, Maggie RATHOS, Ankita SRIVASTAVA, Sreesha SRINIVASA

Filed: 5 Feb 21

Utility

q27ryt998wfhlohnkkevjfkyy

1 Jul 21

Veena Agarwal, Arun Balakrishnan, Giridharan Periyasamy

Filed: 15 Mar 21

Utility

gzqhm3p6rwii8rmvwt5llbhezwco6byucarttx4j2qp45txrbg8w

20 May 21

Milind GHARPURE, Sanjay Kumar SHARMA, Sandesh VISHWASRAO, Prasad VICHARE, Dipak VARAL

Filed: 9 May 18

Utility

00n90lpmg42bk809qwc qhxf185wndtffib

22 Apr 21

The present invention relates to an improved asymmetric synthesis of alpha-branched amines (hereafter referred to as the compound) and relative chiral amines (1″) or its pharmaceutically acceptable salt and derivatives.

Rajender Reddy LELETI, Sharadsrikar KOTTURI, Yogesh WAMAN, Chirag PATEL, Aditya PATWA, Rajesh SHENOY

Filed: 17 Apr 19

Utility

8bdsxed5314rr41m64kkncimxenoeklkq6gny

25 Mar 21

The present invention relates to a novel crystalline polymorphic form of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine hydrochloride; commonly known as vortioxetine hydrochloride (hereafter referred to as the compound (Ia) and process for its preparation comprising of treating the compound (Ia) (as described herein) with a ketone solvent or mixture of ketone solvent with other solvents.

Milind GHARPURE, Sanjay Kumar SHARMA, Nainesh KANSAGARA, Yogesh ZALTE, Pravin THOMBRE, Sudha MENON

Filed: 5 Feb 19

Utility

4iliy9y9jvqr8wn5 uq3q63

4 Mar 21

The present invention relates to an improved asymmetric synthesis of alpha-(diarylmethyl) alkyl amines (hereafter referred to as the compound (1)) or its pharmaceutically acceptable salt and derivatives.

Rajender Reddy LELETI, Sharadsrikar KOTTURI, Yogesh WAMAN, Chirag PATEL, Rajesh SHENOY

Filed: 20 Mar 19

Utility

ue8gv16xy5tdwtv2oxo5me5h41zua2g5awe8fqnw6k7

25 Feb 21

Rajiv SHARMA, Sanjay KUMAR, Vishal MAHAJAN, Komal BAJAJ, Pallavi GODSE

Filed: 2 Nov 20

Utility

y4howtipqt1aawp21td7u0hvtze5qrbr64hzura

11 Nov 20

The present invention provides an improved process for preparation of the L-threo-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) or a salt thereof, which is known as Droxidopa; comprising (a) recovery of the by-product compound (V) (as described herein) from the crude compound (I), and (b) recycling and re-use it for the preparation of droxidopa.

Milind GHARPURE, Ashutosh JAGTAP, Changdev RAUT, Navnath PATIL, Prashant LADKAT, Jaisankar KRISHNAPILLAI, Nirmal Kumar MANOHARAN, Kumaravel KANDASAMY

Filed: 2 Jan 19

Utility

p976d3kqus5ursf8jt0q1oopykm96d164vmucf36 5lv

23 Sep 20

The present invention provides an improved process for preparation of L-threo-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) (Droxidopa) and its salts; comprising (a) reaction of the aldehyde compound (III) (as described herein) with Metal complex (II) (as described herein), and (h) hydrolysis of the compound (IV) obtained from step (a) in presence of acid.

Milind GHARPURE, Ashutosh JAGTAP, Changdev RAUT, Nainesh KANSAGARA, Jaisankar KRISHNAPILLAI, Nirmal Kumar MANOHARAN, Navnath PATIL

Filed: 27 Mar 17

Utility

jgwh0bkj3jak34fc udu1d9t0uf7b9k4

16 Sep 20

The present invention relates to the pyrrolidine substituted with flavone derivatives, represented by the compounds of Formula (I) or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a diastereoisomer thereof for use in the treatment of cancers associated with human papillomavirus.

Swati Ajay PIRAMAL, Muralidhara PADIGARU, Veena R. AGARWAL, Gandhali Ashwin DESHPANDE

Filed: 8 Apr 20

Utility

x6mup cajhjx8ql0f8ue5

10 Jun 20

The present invention relates to a level meter measuring the quality health of a pharmaceutical manufacturing site and which predicts 24/7 audit readiness for quality outcomes, wherein outcome is interpreted using tangible data; referred to as a Quality Health Barometer.

Rashida NAJMI, Monika BORNANI

Filed: 26 Nov 19

Utility

y76h4lmc17utsl7nbdum amd9lt2h1adhxk01cq2p2divdcf

6 May 20

The present invention relates to a pharmaceutical combination comprising a CDK inhibitor and at least one antioxidant enzyme inhibitor for use in the treatment of cancer.

Owe ORWAR, Sreesha SRINIVASA, Prabha MISHRA

Filed: 22 Dec 19

Utility

e482iw7qyalx30ju9tio3

22 Apr 20

Milind GHARPURE, Sanjay Kumar SHARMA, Sandesh VISHWASRAO, Prasad VICHARE, Dipak VARAL

Filed: 8 May 18

Utility

oifl249ow71dhzwo5jbo7l8w4z0xbt0hmkyyo8xs1quy34zhm88 9w

12 Feb 20

The present invention relates to an oral pharmaceutical composition, particularly a tablet, comprising an active ingredient lurasidone or its pharmaceutically acceptable salt(s) or solvate(s) thereof and one or more pharmaceutical excipient(s); and a process for its preparation.

Tejas SHAH, Milan B. AGRAWAL, Narendra PATEL, Devesh BHATT, Umesh BARABDE, Vipan DHALL

Filed: 9 Jan 18

Utility

ibkwnmp15e8tm8u2sf12xj 6wviurensifc3fqfyegj56lyaaercjqw93

16 Oct 19

The present invention provides an improved process for the preparation of N-protected ((3S,4R)-4-(4-fluorophenyl)piperidin-3-yl)methanol (compound (A)) and further its transformation to Paroxetine and its pharmaceutically acceptable salts.

Raghavendar Rao MORTHALA, Arnab ROY, Tapas MAITY, Baswaraj PATLOLLA, Murali RAJAPPA, Nilanjan MAJUMDER, Chirag PATEL, Dhileepkumar KRISHNAMURTHY, Santhosh Reddy JANGARI, Anant JAGTAP, Phani Kumar MANNEM, Pulendarreddy ARWAL

Filed: 1 Sep 16